Volumen: 16 # Number : 2
Publication Date : Mayo - Agosto Year: 2012
Authors: Fantl D.
Abstract: Bortezomib is a drug with a unique mechanism of action
and clearly different from other conventional chemotherapy
agents it has an acceptable safety profile and does not have
an adverse impact on stem cell collection or post stem cell
transplant engraftment. Bortezomib based combinations
revealed a high complete remission and a significantly longer
progression free survival and overall survival. Overall,
these results bortezomib based combinations remain one
of the treatment options for myeloma patients.
Key words: Bortezomib, Proteasoma, Toxicity, Multiple
Myeloma
Pages : 114-119
|
